FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  MILANO VINCENT  (Last) (First) (Middle)					3. E	2. Issuer Name and Ticker or Trading Symbol Aclaris Therapeutics, Inc. [ ACRS ]  3. Date of Earliest Transaction (Month/Day/Year) 06/06/2024						(Ch	5. Relationship of Reporting Person(s) to Iss (Check all applicable)   Director 10% Ov Officer (give title below)  Other (s				ner
C/O ACLARIS THERAPEUTICS, INC. 701 LEE ROAD, SUITE 103				4. I	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	6. Individual or Joint/Group Filing (Check Applicable Line)  Form filed by One Reporting Person					
(Street) WAYNE	PA 19087			Ri	Form filed by More than One Rep Person  Rule 10b5-1(c) Transaction Indication								One Report	ing			
(City) (State) (Zip)					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
		Tab	le I - Nor	n-Deriv	ative	e Se	curities	s Ac	quired, Di	sposed	of, or Be	neficial	y Owned				
1. Title of Security (Instr. 3)  2. Transac Date (Month/D:				Execution Date		Date,	Code (Instr. 5)			Beneficia Owned F	s ally following	Form	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
							Code V	Amour	t (A) o	Price	Reported Transact (Instr. 3 a	action(s)					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Ye	Date,	4. Transa Code (I 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/\)	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e C s s lly D o (l	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$1.03	06/06/2024			A		15,750		(1)	06/05/203	Common Stock	15,750	\$0	15,750 <sup>0</sup>	(2)	D	
Restricted Stock Units	(3)	06/06/2024			A		4,793		(4)	(4)	Common Stock	4,793	\$0	4,793 <sup>(2</sup>	2)	D	

## **Explanation of Responses:**

- 1. The shares subject to this option will vest in twelve equal monthly installments commencing July 6, 2024, subject to Reporting Person's continuous service through each such date.
- 2. This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy.
- 3. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- 4. The shares underlying these restricted stock units will vest on June 6, 2025, subject to the Reporting Person's continuous service through such date.

/s/ Matthew Rothman,

06/10/2024

Attorney-in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.